Project description
An immunotherapy against coeliac disease
Coeliac disease is a genetic autoimmune disorder caused by intolerance to gluten, a protein found in wheat, rye and barley. Currently, the only treatment option for coeliac patients is to follow a lifelong gluten-free diet, which poses a tremendous strain on the entire family. The EU-funded SOMIT project brings forward an immunotherapy as an alternative treatment option for coeliac patients. The treatment aims to reinstall tolerance to gluten by targeting specific immune cells and can be used in children under 5 years of age. Given the high penetrance of coeliac disease, the proposed solution targets a big market for coeliac disease therapeutics.
Objective
Celiac Disease is a debilitating autoimmune disorder that is caused by intolerance to gluten. Although it is the most common genetically-based food intolerance in the world, there are currently no therapeutics available to treat patients. In this project, Allero Therapeutics will collaborate with two leading research institutes (Leiden University Medical Center from the Netherlands and the Veterinary Research Institute from the Czech Republic) to develop a first-in-class therapeutic against Celiac Disease. Specifically, this novel therapeutic consists of an antigen-specific immunotherapy combined with tolerizing agents, which will be delivered to the oromucosa via a proprietary sublingual mouth patch. This project consists of a 6-month multi-disciplinary feasibility study that will:
(1) experimentally demonstrate in vitro and ex vivo Proof of Principle for the novel therapeutic;
(2) research all required (pre)clinical development to build a detailed roadmap for navigating the regulatory landscape;
(3) strengthen and expand the current IP position; and
(4) consolidate all current and future findings into an investor-ready Business Plan.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences basic medicine immunology autoimmune diseases
- medical and health sciences clinical medicine allergology
- medical and health sciences basic medicine immunology immunotherapy
- medical and health sciences clinical medicine gastroenterology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
9070 GENT
Belgium
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.